Adoram Therapeutics Secures Pre-Seed Investment
Summary
This investment will enable Adoram Therapeutics to accelerate the development of its novel small molecule drugs designed to enhance the immune response in cancer patients and address multiple inflammation or autoimmune-related conditions. "We are thrilled to receive this support as it significantly aids our efforts to bring innovative therapies to the clinic," said Dr. David PEJOSKI, co-CEO and co-founder of Adoram Therapeutics. He added, Contributions and endorsement from private investors and FONGIT, empowers Adoram Therapeutics to advance to the next stage of growth and strengthens our position in the Swiss Biotech community. We aim to continue discovering small molecule allosteric modulators for validated GPCR targets for patients in need of efficacious therapies" said Dr Hesham HAMED, co-CEO/CSO of Adoram Therapeutics.Generous grants from the Swiss national innovation agency, Innosuisse, and the Geneva tech transfer office, UNITEC, allowed the conception of these ideas and the delivery of proof-ofconcept studies in immuno-oncology and inflammation. The work done in the Pharmaceutical Biochemistry lab at University of Geneva led by Prof. Scapozza, laid the groundwork for the current advancements.With this investment, Adoram Therapeutics aims to continue its mission of developing safer and more effective immunotherapies for patients with solid tumors and innovative treatments for inflammation-related diseases.